Wednesday, August 26, 2026
60 articles analyzed
Updated Aug 26, 1:27 AM · 60 sources analyzed
Key Takeaways
Amgen's daxdilimab Phase 2 in myositis is complete, but no efficacy data are public yet — ACR 2026 is the key watch.
BMS mavacamten nHCM Phase 3 finished; a positive readout would double the drug's addressable patient population in cardiology.
Pharvaris's Phase 2 HAE prophylaxis trial was terminated — a pipeline blow for a company whose entire thesis rests on oral bradykinin blockade.
🏆 Winner
Eli Lilly — orforglipron Phase 3 obesity trial moves to active non-recruiting, placing a pivotal oral GLP-1 readout on the near-term horizon.
📉 Loser
Pharvaris — Phase 2 HAE prophylaxis trial terminated with no public explanation, materially weakening its single-platform pipeline story.
🔭 Watch Next
Bristol-Myers Squibb's mavacamten Phase 3 nHCM data release — likely at ACC or AHA — is the most consequential pending readout visible in today's sources, with the potential to expand one of cardiology's most-watched franchises.
Amgen's daxdilimab Phase 2 in myositis completes
Amgen's daxdilimab, an anti-ILT7 monoclonal antibody, completed a Phase 2 proof-of-concept study in dermatomyositis and anti-synthetase inflammatory myositis — two rare, difficult-to-treat inflammatory muscle diseases with limited approved options. The trial, registered at ClinicalTrials.gov, listed disease activity reduction at Week 24 as the primary efficacy objective, but no numerical results have been released publicly. Myositis represents an underserved niche where a clean efficacy signal could support a broader type I interferon pathway franchise for Amgen, competing with emerging assets targeting the same biology.
ClinicalTrials.gov ↗Eli Lilly oral GLP-1 orforglipron Phase 3 obesity trial moves to active non-recruiting
A Phase 3 trial of orforglipron — Lilly's oral, non-peptide GLP-1 receptor agonist — in adults with obesity or overweight with weight-related comorbidities is now marked Active, Not Recruiting on ClinicalTrials.gov, indicating enrollment is complete and the trial is in follow-up.
Why it matters
Enrollment completion in this pivotal trial puts a Phase 3 obesity readout on the near-term horizon and represents the most consequential near-term catalyst for whether Lilly can extend its GLP-1 franchise dominance into the oral format ahead of Novo Nordisk's oral semaglutide and other competitors. The investment thesis turns entirely on whether the weight-loss magnitude is competitive with injectable semaglutide.
What to watch
Watch for Lilly to announce top-line Phase 3 obesity data for orforglipron, expected in the near term given the active non-recruiting status, followed by an NDA filing timeline announcement.
Amgen
Daxdilimab in Dermatomyositis / Anti-synthetase Inflammatory Myositis
Primary objective was reduction in disease activity at Week 24 versus placebo. Full numerical results have not yet been released; the trial status is marked Completed on ClinicalTrials.gov but no efficacy data have been publicly disclosed.
Why it matters
Daxdilimab's ILT7 mechanism is differentiated from B7-pathway and JAK inhibitor approaches, and proof-of-concept in myositis would expand the commercial thesis well beyond lupus. Investors will need the actual data readout — likely at a rheumatology congress — before assessing whether Amgen pursues a Phase 3 registration program.
What to watch
Watch for data presentation at ACR Convergence 2026 (November) or a peer-reviewed publication that discloses Week 24 disease activity scores and safety events.
Bristol-Myers Squibb
Mavacamten in Non-obstructive Hypertrophic Cardiomyopathy (nHCM)
The Phase 3 trial evaluating mavacamten's safety, tolerability, and efficacy versus placebo in symptomatic nHCM is marked Completed on ClinicalTrials.gov. No efficacy or safety results have been publicly disclosed from this registry update.
Why it matters
The nHCM indication is where BMS's investment thesis in mavacamten either materially expands or plateaus — obstructive HCM alone supports a solid but bounded commercial opportunity. The absence of disclosed results from a completed Phase 3 means the market is still in the dark, and the data release will be a significant catalyst either way.
What to watch
Watch for BMS to present nHCM Phase 3 results at a major cardiology meeting — ACC or AHA 2026/2027 — and for any subsequent FDA supplemental NDA filing timeline.
Ionis Pharmaceuticals
Eplontersen in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
The CARDIO-TTRansform Phase 3 trial, evaluating eplontersen versus placebo in ATTR-CM on top of standard of care, is now marked Completed on ClinicalTrials.gov. No efficacy or safety numerical results have been disclosed through this registry update.
Why it matters
Ionis's ATTR-CM program is a pipeline anchor, and the CARDIO-TTRansform completion moves the data readout closer to the finish line. The investment question is whether eplontersen can differentiate on TTR suppression depth or convenience against an increasingly crowded field that already includes an orally-dosed competitor.
What to watch
Watch for top-line CARDIO-TTRansform data announcement and a potential NDA submission to FDA, expected to be among Ionis's most significant regulatory catalysts in the near term.
Primary objective was reduction in disease activity at Week 24 versus placebo. Full numerical results have not yet been released; the trial status is marked Completed on ClinicalTrials.gov but no efficacy data have been publicly disclosed.
Why it matters
Myositis is a high-unmet-need space with no FDA-approved therapies for dermatomyositis; a positive signal would give Amgen a foothold in the type I interferon disease space alongside its anifrolumab competitor AstraZeneca.
Analysis
Daxdilimab's ILT7 mechanism is differentiated from B7-pathway and JAK inhibitor approaches, and proof-of-concept in myositis would expand the commercial thesis well beyond lupus. Investors will need the actual data readout — likely at a rheumatology congress — before assessing whether Amgen pursues a Phase 3 registration program.
What to watch
Watch for data presentation at ACR Convergence 2026 (November) or a peer-reviewed publication that discloses Week 24 disease activity scores and safety events.
The Phase 3 trial evaluating mavacamten's safety, tolerability, and efficacy versus placebo in symptomatic nHCM is marked Completed on ClinicalTrials.gov. No efficacy or safety results have been publicly disclosed from this registry update.
Why it matters
Mavacamten (Camzyos) is already approved for obstructive HCM; a successful nHCM readout would roughly double the addressable patient population, making this one of the more consequential pending label expansion datasets in cardiology.
Analysis
The nHCM indication is where BMS's investment thesis in mavacamten either materially expands or plateaus — obstructive HCM alone supports a solid but bounded commercial opportunity. The absence of disclosed results from a completed Phase 3 means the market is still in the dark, and the data release will be a significant catalyst either way.
What to watch
Watch for BMS to present nHCM Phase 3 results at a major cardiology meeting — ACC or AHA 2026/2027 — and for any subsequent FDA supplemental NDA filing timeline.
The CARDIO-TTRansform Phase 3 trial, evaluating eplontersen versus placebo in ATTR-CM on top of standard of care, is now marked Completed on ClinicalTrials.gov. No efficacy or safety numerical results have been disclosed through this registry update.
Why it matters
ATTR-CM is a fiercely competitive market — Pfizer's tafamidis dominates, with alnylam's vutrisiran and BridgeBio's acoramidis as challengers; eplontersen's antisense mechanism and subcutaneous monthly dosing profile will need compelling outcomes data to carve out share.
Analysis
Ionis's ATTR-CM program is a pipeline anchor, and the CARDIO-TTRansform completion moves the data readout closer to the finish line. The investment question is whether eplontersen can differentiate on TTR suppression depth or convenience against an increasingly crowded field that already includes an orally-dosed competitor.
What to watch
Watch for top-line CARDIO-TTRansform data announcement and a potential NDA submission to FDA, expected to be among Ionis's most significant regulatory catalysts in the near term.
A Phase 2 study of LY4100511, an oral small-molecule integrin inhibitor developed by DICE Therapeutics (acquired by Lilly), in moderate-to-severe plaque psoriasis is marked Completed on ClinicalTrials.gov. No efficacy or safety data have been publicly disclosed from this registry update.
Why it matters
Oral options for moderate-to-severe psoriasis remain an active battleground — a clean Phase 2 signal for LY4100511 would strengthen Lilly's dermatology pipeline beyond lebrikizumab and into the large oral convenience market.
Analysis
DICE's oral peptide platform was the core thesis behind Lilly's $2.4 billion acquisition, and LY4100511's Phase 2 completion is an early test of whether that platform can translate in a well-established indication. Lilly will need to show both efficacy and an acceptable GI and systemic tolerability profile to justify advancing to Phase 3 against entrenched biologics.
What to watch
Watch for Lilly to disclose Phase 2 efficacy and safety data for LY4100511 at a dermatology congress — EADV or AAD — and for any Phase 3 go/no-go announcement.
The dose-ranging Phase 2 prophylaxis study of oral PHA-022121 in hereditary angioedema (HAE) Types I and II is marked Terminated on ClinicalTrials.gov. No efficacy or safety numerical results have been disclosed through this registry update; the reason for termination has not been publicly detailed.
Why it matters
HAE is a competitive oral prophylaxis market with Kalvista's sebetralstat and Takeda's established injectable options — a terminated Phase 2 raises questions about Pharvaris's ability to differentiate and narrows its pipeline optionality.
Analysis
A Phase 2 termination in HAE is a meaningful setback for Pharvaris, whose entire value proposition rests on the oral bradykinin B2 receptor antagonist platform. Without a clear explanation — whether for efficacy, safety, or operational reasons — investors will be skeptical about the path forward, and the termination weakens Pharvaris's negotiating position for any potential partnership.
What to watch
Watch for Pharvaris to issue a public explanation for the termination and clarify whether any alternative dosing regimen or formulation will be advanced into a new study.
Small molecule CD28 costimulation blocker shows target engagement in IBD models
Researchers using a split-luciferase screening platform identified a small molecule inhibitor that selectively blocks CD28 costimulation (the second signal T cells need to become fully activated) without disrupting CTLA-4 signaling, reducing pathogenic T-cell responses in inflammatory bowel disease models.
Why it matters
Selective CD28 blockade could offer an immunosuppression profile that is narrower than existing B7-directed biologics like abatacept, potentially with fewer infection-related adverse events — a meaningful differentiator if the selectivity translates to human studies.
Analysis
This is early preclinical work, but the mechanistic framing is commercially interesting: the IBD biologics market is enormous and current therapies still leave a large proportion of patients in inadequate remission. A small molecule with oral potential and selective costimulation blockade would be a genuinely differentiated asset if the selectivity data hold up in more complex systems.
What to watch
Watch for IND-enabling studies or a licensing announcement — the NanoBiT screening platform and lead optimization data make this a candidate for early-stage partnering with a larger immunology player.
Eli Lilly oral GLP-1 orforglipron Phase 3 obesity trial moves to active non-recruiting
A Phase 3 trial of orforglipron — Lilly's oral, non-peptide GLP-1 receptor agonist — in adults with obesity or overweight with weight-related comorbidities is now marked Active, Not Recruiting on ClinicalTrials.gov, indicating enrollment is complete and the trial is in follow-up.
Why it matters
Orforglipron is the leading candidate to bring GLP-1 class weight-loss efficacy to a fully oral, small-molecule format — a formulation advantage that could dramatically expand the addressable market beyond patients willing or able to self-inject.
Analysis
Enrollment completion in this pivotal trial puts a Phase 3 obesity readout on the near-term horizon and represents the most consequential near-term catalyst for whether Lilly can extend its GLP-1 franchise dominance into the oral format ahead of Novo Nordisk's oral semaglutide and other competitors. The investment thesis turns entirely on whether the weight-loss magnitude is competitive with injectable semaglutide.
What to watch
Watch for Lilly to announce top-line Phase 3 obesity data for orforglipron, expected in the near term given the active non-recruiting status, followed by an NDA filing timeline announcement.
Moderna mRNA RSV vaccine pediatric high-risk study completes enrollment phase
A Phase 2 study of Moderna's mRNA-1345 RSV vaccine in children aged 2 to under 18 who are at high risk for RSV complications is marked Completed on ClinicalTrials.gov, covering safety, reactogenicity, and immunogenicity endpoints in the pediatric population.
Why it matters
mRNA-1345 is already approved for older adults (as mRESVIA); pediatric high-risk data would be required to support a label expansion into immunocompromised and high-risk children — a population with significant unmet need and limited current options.
Analysis
RSV prevention in high-risk children is the next commercial frontier in respiratory vaccines after the adult market opened up with nirsevimab and the adult mRNA approvals. Moderna's pediatric Phase 2 completion is a necessary step toward a pivotal program, though the competitive landscape is rapidly filling with AstraZeneca/Sanofi's nirsevimab already holding strong pediatric positioning.
What to watch
Watch for Moderna to release immunogenicity and safety data from this pediatric high-risk cohort, which will determine whether a Phase 3 efficacy trial in children is warranted and feasible.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.
Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse